Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does early letermovir initiation delay engraftment?

Antimicrobial agents and chemotherapy·2026
Same author

Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimaging.

Bone marrow transplantation·2026
Same author

Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee.

Bone marrow transplantation·2026
Same author

Pretransplant CMV-IgG Titers and DNAemia Are Associated With CMV Infections Post Allogeneic Hematopoietic Cell Transplant With or Without Letermovir.

Open forum infectious diseases·2026
Same author

Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2024

Related Experiment Video

Updated: Jun 24, 2025

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

5.4K

An Update on Breakthrough Invasive Mold Infections.

Vera Portillo1,2, Dionysios Neofytos3

  • 1Division of Infectious Diseases, University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland. veraportillo@gmail.com.

Mycopathologia
|June 13, 2024
PubMed
Summary

Breakthrough mold infections (bIMI) are rising due to antifungal prophylaxis and high-risk patients. Current treatments include amphotericin-B and azole switches, with future strategies focusing on personalized susceptibility and new agents.

Keywords:
Breakthrough fungal infectionsBreakthrough mold infectionsPosaconazole

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

515
Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
04:37

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections

Published on: February 2, 2024

781

Related Experiment Videos

Last Updated: Jun 24, 2025

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

5.4K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

515
Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
04:37

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections

Published on: February 2, 2024

781

Area of Science:

  • Mycology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Increasing incidence of breakthrough mold infections (bIMI) in immunocompromised patients.
  • Challenges in treating these infections due to resistant fungal strains and complex host factors.
  • Limitations of current diagnostic and therapeutic options leading to high mortality rates.

Purpose of the Study:

  • To review the current landscape of breakthrough mold infections (bIMI).
  • To discuss the pharmacokinetic, fungal, and host factors influencing bIMI emergence.
  • To explore current and future therapeutic strategies for managing bIMI.

Main Methods:

  • Literature review of recent studies on bIMI.
  • Analysis of pharmacokinetic data for antifungal agents.
  • Examination of host and fungal genetic factors implicated in bIMI.

Main Results:

  • Breakthrough mold infections (bIMI) are increasingly prevalent, driven by antifungal prophylaxis and vulnerable patient populations.
  • Amphotericin-B and azole-based therapies are primary treatment modalities, with frequent class switching observed.
  • Pharmacokinetic properties, host genetics, and fungal characteristics significantly influence bIMI development.

Conclusions:

  • Despite advances, bIMI continue to pose a significant mortality risk.
  • Personalized prophylaxis and treatment strategies, informed by individual susceptibility, are crucial for future management.
  • Development of novel antifungal agents and improved diagnostics are essential to reduce bIMI morbidity and mortality.